^
    Back
    Association details:
    Biomarker:BRAF V600E
    Cancer:Astrocytoma
    Drug:Tafinlar (dabrafenib) (BRAF inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Adjuvant Treatment useful in certain circumstance...Pilocytic astrocytoma, PXA, ganglioglioma if BRAF V600E activating Mutation
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Melanoma)
    New
    Excerpt:
    TAFINLAR is a kinase inhibitor indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test.
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    Childs Nerv Syst
    Title:

    Dabrafenib in BRAFV600E mutant pilocytic astrocytoma in a pediatric patient

    Excerpt:
    We report a case of successful treatment of BRAFV600E immunopositive optic pathway PA in a child with dabrafenib.
    DOI:
    10.1007/s00381-019-04346-2
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    Spandidos Publications
    Title:

    Dabrafenib in patients with recurrent, BRAF V600E mutated malignant glioma and leptomeningeal disease

    Excerpt:
    The first patient (male) presented at the age of 24...histopathology showed an anaplastic pleomorphic xanthoastrocytoma….Immunohistochemistry as well as DNA-sequencing revealed BRAF V600E mutation….Two months after radiotherapy we initiated oral dabrafenib treatment with 150 mg twice daily....All lesions fully regressed and all CSF parameters normalized. To date, he is on dabrafenib for 27 months and MRI still shows complete remission without contrast enhancing lesions...
    DOI:
    https://doi.org/10.3892/or.2017.6013